| Abstrakt: |
The article discusses the importance of avoiding patent infringement at trade shows, specifically in light of the recent case Edwards v. Meril. It explains that trade shows are crucial for medical device professionals to showcase new products and network, but activities at these events can potentially lead to patent infringement. The article highlights the Safe Harbor provision in U.S. patent law, which exempts certain activities related to obtaining FDA approval from infringement. The case between Edwards Lifesciences Corporation and Meril Life Sciences PVT. LTD. provides insight into best practices for exhibitors at trade shows, particularly when presenting new technologies. The court ruled in favor of Meril, finding that their actions fell within the Safe Harbor provision and were not infringing. The article concludes by suggesting best practices to minimize patent infringement risks at trade shows, such as documenting intent, executing non-disclosure agreements, conducting training, and seeking legal counsel. Overall, the article emphasizes the importance of understanding patent law and FDA regulations to navigate the legal landscape associated with bringing new medical technologies to market. [Extracted from the article] |
